A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

BofA Securities maintained a Buy rating on Eli Lilly stock (NYSE:LLY), with a price target set at $997.00. With a market capitalization of $706 billion and impressive revenue growth of 27.4% over the ...

The study's primary endpoint of progression ... the board of directors of Eli Lilly and Company (NYSE: LLY) approved a new $15 billion share repurchase program. The company's prior $5 billion ...

Novo Nordisk (NVO) stock gains on promising Phase 1/2 data for the drugmaker's new weight loss drug amycretin. Read more here ...

Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

Eli Lilly says a new starting dose regimen for ... and other anti-amyloid drugs and can be life-threatening. In the new study, there was also a larger 67% reduction in ARIA-E among patients ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...